Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent
暂无分享,去创建一个
M. Pencina | S. Normand | J. Massaro | L. Mauri | S. Bangalore | D. Holmes | D. Cohen | D. Kereiakes | D. Cutlip | S. Wiviott | D. Cohen | D. Cohen
[1] M. Jeong,et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. , 2010, The New England journal of medicine.
[2] M. Keltai,et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial , 2008, The Lancet.
[3] B. Gersh. Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents , 2008 .
[4] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[5] Simon Wandel,et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.
[6] Deepak L. Bhatt,et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.
[7] Susan Smyth,et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. , 2007, JAMA.
[8] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[9] Ralph D'Agostino,et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.
[10] S. Pocock,et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.
[11] Neville Kukreja,et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.
[12] C. Grines,et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Journal of the American College of Cardiology.
[13] C. Grines,et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[14] David B Matchar,et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.
[15] Patrick Hunziker,et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.
[16] Patrice Cacoub,et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.
[17] D. Baim,et al. Beyond Restenosis: Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials , 2004, Circulation.
[18] G. Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.
[19] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[20] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[21] S. Yusuf,et al. Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups , 2002, Circulation.
[22] Salim Yusuf,et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.
[23] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .
[24] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[25] Y. Hochberg. A sharper Bonferroni procedure for multiple tests of significance , 1988 .
[26] E. Lakatos,et al. Sample sizes based on the log-rank statistic in complex clinical trials. , 1988, Biometrics.